220.127.116.11.3 Pharmacokinetic properties
Erysafe , like other macrolide antibiotics, is orally administered. Because of its acid instability, however, Erysafe exhibits high interindividual variability in oral bioavailability, with values ranging from 15% to 45%. The maximal plasma concentration after a typical 250–500 mg oral dose is achieved after approximately 4–5 h, and ranges from 0.3 to 3.5 μg mL −1 . Erysafe has a low volume of distribution (0.64 L kg −1 ), which contributes to its short half-life (approximately 1.4 h) and necessitates a frequent dosing schedule, typically 250 mg four times a day or 500 mg twice a day. Erysafe is metabolized in the liver, and its major metabolites are the demethylated product at the dimethylamino group, the N-oxide of the desosamine, and des-cladinose Erysafe, all of which have much reduced antibacterial potency. Erysafe and its metabolites are eliminated mainly in bile. In terms of tissue distribution, higher concentrations are found in tissues such as the lung and tonsils than in plasma. Like other macrolides, it accumulates in phagocytic cells. 158 Since phagocytic cells (macrophages) migrate to the site of infection and release the macrolide, this is considered to be significant in raising the local concentration of the antibiotic. Erysafe is 65–90% protein bound with α1-glycoprotein as the main binding partner. The key pharmacokinetic values are summarized in Table 1 . 159,160 As mentioned earlier, one serious drawback of Erysafe is its instability under acidic conditions such as those encountered in the stomach. With acid catalysis, Erysafe undergoes a series of transformations promoted by the proximity of functional groups and by the entropic factors. 161 Scheme 1 demonstrates the initial change that occurs, as an internal acetal develops and quickly loses a molecule of water to form a cyclic enol ether. These transformations irreversibly result in microbiologically inactive products. Due to this vulnerability, Erysafe's effectiveness is threatened by both low bioavailability and high interpatient variability. Enteric-coated tablets were developed with some success to protect Erysafe from degradation and to mask its bitter taste. 162
Table 1 . Oral pharmacokinetic properties of first- and second-generation macrolides
If you suspect an overdose, contact a poison control center or emergency room immediately. You can get in touch with a poison control center at (800) 222-1222.
What is Erysafe used for?
Erysafe is prescribed by dermatologists for a variety of skin conditions including:
Erysafe is particularly useful in individuals allergic to penicillin and in children that are too young for a tetracycline.
It is active against many gram-positive organisms (including Staphylococcus aureus, Streptococcus pyogenes, corynebacteria and clostridia) and some gram-negative organisms (Neisseria gonorrhoeae, the cause of gonorrhoea). It is also effective for mycoplasma infections, syphilis and chlamydia.
Increasing bacterial resistance to Erysafe is reported. The prolonged use of Erysafe has been questioned in dermatology because it can lead to bacterial resistance to the pathogen , Staphylococcus aureus (see MRSA), as well as resistance to acne bacteria (Cutibacterium acnes).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Erysafe Base Filmtab tablets and other antibacterial drugs, Erysafe Base Filmtab (Erysafe tablets) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Erysafe Base Filmtab (Erysafe tablets) tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes; Streptococcus pneumoniae; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the Erysafe concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.)
Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Pertussis (whooping cough) caused by Bordetella pertussis. Erysafe is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that Erysafe may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Diphtheria: Infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma-In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral Erysafes only). Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: Erythrocin® Lactobionate-I.V. (Erysafe lactobionate for injection, USP) followed by Erysafe base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving Erysafe as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Erysafes are indicated for treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, Erysafe is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. 3
When tetracyclines are contraindicated or not tolerated, Erysafe is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. 3
Primary syphilis caused by Treponema pallidum. Erysafe (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy.
Legionnaires' Disease caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that Erysafe may be effective in treating Legionnaires' Disease.
home drugs a-z list Erysafe Base Filmtab(Erysafe Tablets) side effects drug center
Find Lowest Prices on
Erysafe Base Filmtab (Erysafe) is macrolide antibiotic used to treat people that are infected with organisms susceptible to Erysafe. Some of the diseases Erysafe Base Filmtab treats are mild to moderate upper and lower respiratory tract infections, listeriosis, diphtheria, pertussis (whooping cough), skin infections and many others. Erysafe Base Filmtab is available in generic form. Common side effects of Erysafe Base Filmtabs include:
The adult dose of Erysafe Base Filmtab is one 250 mg tablet 4 times per day with a maximum dose of 4 grams per 24 hours while the 500 mg tablet is twice a day (total doses over 1 gram per day should be divided into 4 doses per 24 hours). Pediatric doses range from 30 to 50 mg/Kg/day (milligrams per Kilogram per 24 hours), but should not to exceed 4g per day. Patients are advised to take Erysafe Base Filmtab tablets without food, at least ½ hour up to 2 hrs (the preferred time interval) before eating food. Erysafe Base Filmtabs may interact with ergotamine, dihydroergotamine, benzodiazepines, HMG-CoA reductase inhibitors, sildenafil, cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, bromocriptine, cisapride, pimozide, astemizole, terfenadine, hexobarbital, phenytoin, valproate, and astemizole. Tell your doctor if you are pregnant or plan to become pregnant before using Erysafe Base Filmtab; it is unknown if it will affect a fetus. Erysafe Base Filmtab passes into breast milk. Consult your doctor before breastfeeding.
Our Erysafe Base Filmtabs Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Diphtheria is a disease that causes symptoms and signs such as fever, enlarged lymph nodes, and swallowing problems. Erysafe is the primary treatment for diphtheria. Vaccines that prevent diphtheria include the DTaP, Tdap, DT, and Td.
8. Cautions with other medicines
There are some medicines that don't mix well with Erysafe.
Tell your doctor if you're taking these medicines before you start Erysafe:
- antihistamine medicines, such as astemizole, terfenadine or mizolastine
- an anti-sickness medicine called domperidone
- medicines for mental health problems called pimozide and amisulpride
- migraine medicines called ergotamine and dihrydroergotamine
- a cholesterol-lowering medicine called simvastatin
- a bladder weakness medicine called tolterodine
Missed Dose of Erysafe
If you miss a dose of Erysafe, try to take it as soon as you remember.
However, if it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Don't double up to make up for a missed dose.
Erysafe is one of the macrolides, a large group of structurally related antibiotics that inhibit protein synthesis. Erysafe has been shown to bind to the large ribosomal subunit in the peptidyltransferase region of the 23S ribosomal RNA (rRNA). Resistance can arise from mutations in at least three different genes encoding large subunit ribosomal proteins. Curiously, in E. coli, genetic elimination of ribosomal protein L11 makes the cells hypersensitive to Erysafe. Resistance can also arise from specific mutations in the gene encoding 23S rRNA, mutations which must be constructed in organisms like E. coli that have multiple copies of this gene. These mutations are in a region of the 23S rRNA which is protected by specific methylation in the organism that produces Erysafe. Methylation at this site in E. coli leads to Erysafe resistance, but the gene that encodes the specific methylase must be acquired by horizontal gene transfer.
Erysafe is a motilin receptor agonist (a G-protein-coupled receptor that stimulates contractions of smooth muscle in the gut) and has been used in the treatment of diabetic gastroparesis.
7. Pregnancy and breastfeeding
It's usually safe to take Erysafe during pregnancy and while breastfeeding.
For more information about how Erysafe can affect you and your baby during pregnancy, read this leaflet on the Best Use of Medicines in Pregnancy (BUMPS) website.
How should this medicine be used?
Erysafe comes as a capsule, tablet, delayed-release (releases the medication in the intestine to prevent break-down of the medication by stomach acids) capsule, delayed-release tablet, and an oral suspension (liquid) to take by mouth. It usually is taken with or without food every 6 hours (four times a day), every 8 hours (three times a day), or every 12 hours (twice a day). Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take Erysafe exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Shake the suspension well before each use to mix the medication evenly.
If you are taking the suspension, do not use a household spoon to measure your dose. Use the measuring spoon, dropper, or cup that came with the medication or use a spoon made especially for measuring medication.
Swallow the capsules and tablets whole with a full glass of water; do not chew or crush them.
Continue to take Erysafe even if you feel well. Do not stop taking Erysafe without talking to your doctor.
6. How to cope with s >
What to do about:
- feeling sick (nausea) - stick to simple meals and do not eat rich or spicy food while you're taking this medicine. It might help to take your Erysafe with a meal or snack.
- being sick (vomiting) and diarrhoea - drink lots of fluids, such as water or squash - take small, frequent sips if you feel sick to avoid dehydration. Signs of dehydration include peeing less than usual or having strong-smelling pee. Do not take any other medicines without speaking to a pharmacist or doctor.
- stomach cramps - try to rest and relax. It can help to eat and drink slowly and have smaller and more frequent meals. Putting a heat pad or covered hot water bottle on your stomach may also help. If you are in a lot of pain, speak to your pharmacist or doctor.
- loss of appetite - eat when you would usually expect to be hungry. If it helps, eat smaller meals more often than usual. Snack when you're hungry.
- bloating and indigestion - try not to eat foods that cause wind (like lentils, peas, beans and onions). Eat smaller meals, eat and drink slowly, and exercise regularly. Pharmacy medicines like simethicone can also help.
Updated: March 29, 2019
This article was co-authored by Theodore Leng, MD. Dr. Leng is a Board Certified Ophthalmologist and Vitreoretinal Surgeon at Stanford University. He completed his Vitreoretinal surgical fellowship at Stanford University in 2010.
There are 20 references cited in this article, which can be found at the bottom of the page.
If you have a bacterial infection in your eye or your doctor wants to prevent one from happening, then you need an antibiotic, prescribed by a doctor, to treat the problem. One of the most commonly prescribed antibiotics for bacterial eye infections is Erysafe. Erysafe ointment can help kill infections of the eye caused by bacteria. Some of the most w >
Before using Erysafe, tell your doctor or pharmacist if you are allergic to it; or to other macrolide antibiotics (such as clarithromycin); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Before using this medication, tell your doctor or pharmacist your medical history, especially of: contact lens use.
After you apply this drug, your vision may become temporarily blurred. Do not drive, use machinery, or do any activity that requires clear vision until you are sure you can perform such activities safely.
Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).
During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.
It is not known whether Erysafe passes into breast milk when given as an eye ointment. It is unlikely to harm a nursing infant. Consult your doctor before breast-feeding.
Erysafe eye ointment may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
- redness, itching, stinging, or burning of the eye
Erysafe eye ointment may cause other side effects. Call your doctor if you have any unusual problems while using this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).